PCM
SWTX

Penserra Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Penserra Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,130
Closed -$71K – 1543
2021
Q3 		$71K Buy
1,130
+15
+1% +$1.16K ﹤0.01% 939
2021
Q2 		$91K Buy
1,115
+5
+0.5% +$380 ﹤0.01% 824
2021
Q1 		$81K Sell
1,110
-15
-1% -$1.18K ﹤0.01% 723
2020
Q4 		$81K Buy
+1,125
New +$72.4K ﹤0.01% 618

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Penserra Capital Management's SWTX Position: Q4 2021 in Review

Penserra Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2021, closing a stake of 1,130 shares — an estimated $71K sold.

Penserra Capital Management first reported a position in SWTX in Q4 2020 and held it in 4 quarters. The position peaked at $91K in Q2 2021. 144 funds tracked by Wall St. Rank hold SWTX as of Q4 2021.

  • Penserra Capital Management reported no remaining SpringWorks Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,130 SpringWorks Therapeutics shares in Q4 2021, an estimated $71K.
  • Penserra Capital Management first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's SpringWorks Therapeutics position peaked at $91K in Q2 2021.
  • 144 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.